GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 4.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 136,892 shares of the company’s stock after selling 5,847 shares during the period. Thrivent Financial for Lutherans’ holdings in GoodRx were worth $1,068,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Canada Pension Plan Investment Board raised its position in shares of GoodRx by 5.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 166,142 shares of the company’s stock worth $1,296,000 after acquiring an additional 9,200 shares in the last quarter. XTX Topco Ltd raised its position in shares of GoodRx by 42.4% during the 2nd quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock worth $231,000 after acquiring an additional 8,801 shares in the last quarter. Plato Investment Management Ltd acquired a new stake in shares of GoodRx during the 2nd quarter worth about $43,000. Cornercap Investment Counsel Inc. raised its position in shares of GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after acquiring an additional 1,266 shares in the last quarter. Finally, American Century Companies Inc. acquired a new stake in shares of GoodRx during the 2nd quarter worth about $18,183,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on GDRX. Citigroup dropped their price target on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. UBS Group dropped their price target on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research note on Friday, August 16th. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research note on Friday, August 9th. Finally, Morgan Stanley raised their price target on GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research note on Monday, June 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.36.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.17% of the stock is currently owned by insiders.

GoodRx Stock Up 3.1 %

GoodRx stock opened at $7.09 on Friday. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ratio of 7.32. GoodRx Holdings, Inc. has a 1-year low of $4.14 and a 1-year high of $9.26. The company has a market cap of $2.66 billion, a PE ratio of -709.00, a price-to-earnings-growth ratio of 3.38 and a beta of 1.37. The stock’s 50 day moving average price is $7.62 and its 200 day moving average price is $7.57.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business had revenue of $200.60 million during the quarter, compared to analysts’ expectations of $200.47 million. During the same quarter last year, the firm earned $0.02 earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. On average, sell-side analysts predict that GoodRx Holdings, Inc. will post 0.14 EPS for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.